Hugh Ashurst, MD
Internal Medicine · Mobile, ALNPI 1952309965
Payments from drug & device makers
Across 394 payments — averaging $13.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$774
- Novartis$520
- Pfizer$459
- Novo Nordisk$436
- AbbVie$398
- Lilly USA, LLC$393
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,37599%
- Education$391%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 58 | $774 |
| Novartis | 32 | $520 |
| Pfizer | 35 | $459 |
| Novo Nordisk | 59 | $436 |
| AbbVie(2 entities) | 27 | $398 |
| Lilly USA, LLC | 27 | $393 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $322 |
| Bayer | 16 | $267 |
| Kowa Pharmaceuticals America, Inc. | 19 | $199 |
| Sanofi-aventis U.S. LLC | 12 | $198 |
| Amgen | 14 | $189 |
| Merck | 13 | $184 |
| GSK | 9 | $167 |
| AstraZeneca | 10 | $165 |
| Boehringer Ingelheim | 7 | $113 |
| Otsuka America Pharmaceutical, Inc. | 4 | $74 |
| Astellas Pharma US Inc | 4 | $58 |
| Sunovion Pharmaceuticals Inc. | 3 | $48 |
| Daiichi Sankyo Inc. | 3 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $41 |
| Phathom Pharmaceuticals, Inc. | 2 | $35 |
| Exact Sciences | 2 | $33 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| Nevro Corp. | 1 | $26 |
| Shield Therapeutics Inc | 1 | $24 |
| Eisai Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Abbott | 1 | $22 |
| Boston Scientific | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Lundbeck LLC | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
How this compares
$5,414 in reported general payments places this provider in the 85th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 240 | $248,588 |
| MounjaroTirzepatide | 113 | $127,469 |
| EliquisApixaban | 103 | $69,264 |
| JardianceEmpagliflozin | 56 | $50,215 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 44 | $39,053 |
| RybelsusSemaglutide | 32 | $31,038 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 27 | $26,309 |
| FarxigaDapagliflozin Propanediol | 37 | $26,223 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $20,761 |
| XareltoRivaroxaban | 26 | $20,510 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $20,392 |
| TrulicityDulaglutide | 18 | $19,504 |
| Tresiba Flextouch U-100Insulin Degludec | 40 | $18,141 |
| EntrestoSacubitril/Valsartan | 23 | $11,251 |
| JanuviaSitagliptin Phosphate | 15 | $10,295 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus | $436 | $318,679316 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30 | $393 | $150,170155 claims |
| PfizerEliquis | $459 | $69,264103 claims |
| Boehringer IngelheimJardiance, Synjardy | $113 | $56,95267 claims |
| AstraZenecaFarxiga, Symbicort | $165 | $28,91549 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $198 | $26,30927 claims |
| GSKTrelegy Ellipta | $167 | $20,76126 claims |
| Johnson & JohnsonXarelto | $774 | $20,51026 claims |
| NovartisEntresto | $520 | $11,25123 claims |
| MerckJanuvia | $184 | $10,29515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Mobile
- Harry StuddardMobile$12.9M
- Thomas McKelveyMobile$365K
- Mary HonkanenMobile$302K
- Bobby WrightsMobile$89K
- Rahel AzizMobile$67K
- Jamie CaudillMobile$52K
- Thomas GarthMobile$48K
- Lin LiMobile$45K
- Edward CarlosMobile$26K
- Donald SandersMobile$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.